Seronegative neuromyelitis optica spectrum - The challenges on disease definition and pathogenesis;O espectro da neuromielite optica seronegativa - Os desafios na definição da doença e sua patogênese

Arquivos de Neuro-Psiquiatria

Volumn 72, Issue 6, 2014, Pages 445-450

  Sato, Douglas Kazutoshi ^a,b   Callegaro, Dagoberto ^b   Lana Peixoto, Marco Aurélio ^c   Nakashima, Ichiro ^a   Fujihara, Kazuo ^d  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibody; Aquaporin 4; Differential diagnosis; Myelin oligodendrocyte glycoprotein; Myelitis; Neuromyelitis optica; Optic neuritis

Indexed keywords

AQUAPORIN 4 ANTIBODY; C REACTIVE PROTEIN; CD19 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 6; INTERLEUKIN 8; METHYLPREDNISOLONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN S100B; STAT3 PROTEIN; AQUAPORIN 4; AUTOANTIBODY;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; ATROPHY; AXONAL INJURY; BRAIN DAMAGE; CASE REPORT; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOASSAY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATHOGENESIS; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; NEUROMYELITIS OPTICA; SPINAL CORD INJURIES;

AGED; AQUAPORIN 4; AUTOANTIBODIES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; SPINAL CORD INJURIES;

EID: 84903273805     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/0004-282X20140032     Document Type: Article

References (60)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
2. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 2013;10:8.
3. Devic E. Myelite subaiguë compliquée de névrite optique. Bull Med 1894;8:1033-1034.
4. Gault F. De la neuromyélite optique aiguë (Thèsis). Lyon, 1894.
5. Miyazawa I, Fujihara K, Itoyama Y. Neuromyelitis optica (Devic disease) and optic-spinal form multiple sclerosis. No To Shinkei (Brain and nerve) 2001;53:901-910.
6. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrumof neuromyelitis optica. Lancet Neurol 2007;6:805-815.
7. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-396.
8. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-1482.
9. Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin- 4 autoimmunity. Mult Scler 2010;16:1229-1236.
10. Sato D, Fujihara K. Atypical presentations of neuromyelitis optica. Arq Neuropsiquiatr 2011;69:824-828.
11. Lana-Peixoto MA, Callegaro D. The expanded spectrum of neuromyelitis optica: evidences for a new definition. Arq Neuropsiquiatr 2012;70:807-813.
12. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
13. Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibodypositive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013;80:2210-2216.
14. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
15. Ratelade J, Asavapanumas N, Ritchie AM, Wemlinger S, Bennett JL, Verkman AS. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol 2013;126:699-709.
16. Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 2011;70:943-954.
17. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.
18. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461.
19. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224-1234.
20. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
21. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivitydependent entity. Neurology 2013;80:2194-2200.
22. Wingerchuk DM, Weinshenker BG. Acute Disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica. Continuum 2013;19:944-967.
23. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834-1849.
24. Baba T, Nakashima I, Kanbayashi T, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol 2009;256:287-288.
25. Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012;69:1026-1031.
26. Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: A cross-sectional study. Neurology 2011;77:652-658.
27. Elsone L, Townsend T, Mutch K, et al. Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler 2013;19:475-479.
28. Sato D, Fujihara K. Neuromyelitis optica without typical opticospinal phenotype. Mult Scler 2010;16:1154-1155.
29. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-968.
30. Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005;11:617-621.
31. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
32. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72:712-717.
33. Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler 2014;20:695-704.
34. Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013;80:1330-1337.
35. Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 2008;79:1075-1078.
36. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 2008;255:163-170.
37. Nakashima I, Fujihara K, Sato S, Itoyama Y. Oligoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis. J Neuroimmunol 2005;159:133-136.
38. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208-216.
39. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010;16:1443-1452.
40. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011;108:3701-3706.
41. Harris TJ, Grosso JF, Yen H-R, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17- dependent autoimmunity. J Immunol 2007;179:4313-4317.
42. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173-1175.
43. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013;23:827-831.
44. Kieseier BC, Stuve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 2013;70:390-393.
45. Sato DK, Misu T, Rocha CF, et al. Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: Diagnostic considerations. Mult Scler 2014;20:621-626.
46. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
47. Nakajima H, Hosokawa T, Sugino M, et al. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol 2010;10:45.
48. Kitley J, Leite M, George J, Palace J. The differential diagnosis of longitudinally extensive transverse myelitis. Multiple Sclerosis Journal 2012;18:271-285.
49. Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler 2011;17:1527-1530.
50. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
51. Fujihara K, Leite MI. Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges. Neurology 2013;80:2176-2177.
52. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197-1204.
53. Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 2012;3:58-73.
54. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011;8:184.
55. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-1277.
56. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-481.
57. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol 2014;71:276-283.
58. Weinshenker BG, Wingerchuk DM. The two faces of neuromyelitis optica. Neurology 2014;82:466-467.
59. Kezuka T, Usui Y, Yamakawa N, et al. Relationship between NMOantibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol 2012;32:107-110.
60. O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211-217.